Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-007 Topical Gel for HSIL of the Cervix
NCT00285207Phase 2Completed
- Sponsor
- Tigris Pharmaceuticals, Inc.
- Start
- Jan 2006
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Squamous Intraepithelial Lesion (SIL) comparing Placebo with A007 (2 arms). Primary endpoint: Pathological Response at 4 months. Started Jan 2006; status: completed.
02
Drugs
sivifene
03
Conditions
Squamous Intraepithelial Lesion (SIL)
Beyond the preview
Go deeper on NCT00285207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00285207.